Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00002598]
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00002598]
Bio2RDF identifier
NCT00002598
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00002598
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... chronic myelogenous leukemia.
brief title [clinicaltrials_vocabulary:brief-title]
Combination Chemotherapy and I ...... h Chronic Myelogenous Leukemia
completion date [clinicaltrials_vocabulary:completion-date]
2004-06-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... or this study within 4 years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
atypical chronic myeloid leukemia, BCR-ABL1 negative
blastic phase chronic myelogenous leukemia
relapsing chronic myelogenous leukemia
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-06-24T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00002598
official title [clinicaltrials_vocabulary:official-title]
A PHASE II STUDY OF MITOXANTRO ...... NIC MYELOGENOUS LEUKEMIA (CML)
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-06-01T00:00:00Z
secondary id [clinicaltrials_vocabulary:secondary-id]
CDR0000063832
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1994-06-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-06-01T00:00:00Z
identifier
clinicaltrials:NCT00002598
title
Combination Chemotherapy and I ...... h Chronic Myelogenous Leukemia
@en
type
label
Combination Chemotherapy and I ...... a [clinicaltrials:NCT00002598]
@en